Design Therapeutics, Inc. SEC filings DSGN

Design Therapeutics, Inc. has 268 filings in SEC EDGAR's recent list, going back to Mar 20, 2020. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
S-3 Shelf registration Nov 4, 2026 —
424B5 Prospectus supplement Nov 4, 2026 —
S-8 Employee stock plan registration Mar 9, 2026 —
S-3 Shelf registration May 7, 2025 —
S-8 Employee stock plan registration Mar 10, 2025 —
S-8 Employee stock plan registration Mar 19, 2024 —
S-8 Employee stock plan registration Mar 14, 2023 —
S-3 Shelf registration Apr 27, 2022 —
S-8 Employee stock plan registration Mar 10, 2022 —
S-8 Employee stock plan registration Mar 26, 2021 —
424B4 Prospectus Mar 26, 2021 —
S-1/A Amended registration statement Mar 22, 2021 —
S-1 Registration statement Mar 5, 2021 —

Showing 13 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
DSGN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Carlsbad, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1807120

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.